Salivary Phosphorus and Level of Kidney Function

Assessment of the Relationship Between Salivary Phosphorus and Level of Kidney Function

The specific purpose of this study is to describe the relationship between salivary phosphorus and kidney function, specifically as it relates to serum phosphorus, FGF23, PTH, vitamin D status and urinary excretion of phosphorus.

Study Overview

• Status: Completed
• Conditions: Chronic Kidney Disease

Detailed Description

Previous studies have demonstrated that salivary phosphate levels are elevated in patients with chronic kidney disease and that there is a direct and linear correlation between serum phosphorus and salivary phosphorus. However, data regarding the relationship between salivary phosphate levels and stage of kidney disease (estimated glomerular filtration rate (eGFR) is lacking; as such, this study seeks to examine that relationship.

There is a normal circadian rhythm to serum phosphorus with a mid-afternoon peak at approximately 3 PM and a nadir at approximately 7-11 AM. Furthermore it has been demonstrated that a fasting serum phosphorus level at 8 AM is NOT indicative of 24 hour mean serum phosphorus. Thus the relationship between salivary phosphorous and serum phosphorus may vary over the course of the day.

This is a single-center study in which saliva, urine, and serum will be collected at two time points in a minimum of 105 subjects with various degrees of renal function (not on dialysis). Assignment to the renal group will be based upon the Visit 2 estimated glomerular filtration rate value. Enrollment in each group will continue at random until the target of 15 subjects per group is achieved. It is possible that an individual group may exceed the target enrollment number as their assignment will occur retrospectively.

All subjects will be required to have their morning assessment conducted between the hours of 7AM and 11AM. Clinical chemistry, serum phosphorus, intact parathyroid hormone(iPTH), plasma fibroblast growth factor 23 (FGF-23),serum 1,25 di-hydroxyvitamin D, serum 25-OH vitamin D, and a spot urine will be collected. A 24-hour urine sample will also be collected.

Passive and stimulated salivary collection will occur. The salivary collection must occur in a fasting state with nothing to eat or drink for at least 90 minutes prior to the collection.

Subjects will be permitted to leave the facility. They will be instructed to consume a lunch of their choice between the hours of 1100AM and 1200PM. They will be instructed to eat nothing after 1200PM. Subjects will return to the clinic for Visit 3 as directed by the study staff. Visit 3 will be conducted between 1PM and 4PM. Laboratory assessments, salivary collections, and spot urines will be collected at Visit 3. A dietary recall of intake at Visit 2 and 3 will also be completed.

• Study Type: Observational
• Enrollment (Anticipated): 105

Contacts and Locations

Study Locations

• United States
  • Colorado
    • Denver, Colorado, United States, 80230
      • Denver Nephrologists, PC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Normal healthy population an individuals with chronic kidney disease not on dialysis

Description

Inclusion Criteria:

• Men or women greater than 18 years of age.
• The subject has voluntarily signed and dated the most recent informed consent form approved by an Institutional Review Board (IRB).

Exclusion Criteria:

• Receiving hemodialysis.
• Receiving or has received an investigational product (or is currently using an investigational device) within 28 days prior to Visit 2.
• Evidence of active and clinically significant infection at Visit 2.
• Dental work within 48 hours prior to Visit 2.

Study Plan

How is the study designed?

Number of groups / cohorts

7

Cohorts and Interventions

Group / Cohort
Renal Function Group #1; Creatinine clearance > 90 mL/min
Renal Function Group #2; Creatinine clearance 60-69 mL/min
Renal Function Group #3; Creatinine clearance 50-59 mL/min
Renal Function Group #4; Creatinine clearance 40-49 mL/min
Renal Function Group #5; Creatinine clearance 30-39 mL/min
Renal Function Group #6; Creatinine clearance 20-29 mL/min
Renal Function Group #7; Creatinine clearance < 20 mL/min (not on dialysis)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation between fasting salivary phosphorus and estimated glomerular filtration rate	subjects with various levels of estimated glomerular filtration rate will have a single assessment in the fasted state of salivary phosphorus	single value between 7-11 am
Correlation between post meal salivary phosphorus and estimated glomerular filtration rate	subjects with various levels of estimated glomerular filtration rate will have a single assessment in the fed state (meal between 11 am - 12 noon) of salivary phosphorus measured between 1-4 pm	single value after meal between 1-4 pm

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
correlation of fasting salivary phosphorus with plasma fibroblast growth factor 23 levels(FGF-23)	subjects will have plasma FGF23 measured in the fasting state between 7-11 am and correlation made with simultaneous assessment of salivary phosphorus	single AM measurement between 7-11 am
Correlation between fasting salivary phosphorus and serum 1,25 vitamin D levels.	subjects will have serum 1,25 vitamin D measured in the fasting state between 7-11 am and correlation made with simultaneous assessment of salivary phosphorus	single AM measurement between 7-11 am
Correlation between fasting salivary phosphorus and serum intact parathyroid hormone (iPTH) levels.	subjects will have serum intact parathyroid hormone measured in the fasting state between 7-11 am and correlation made with simultaneous assessment of salivary phosphorus	single AM measurement between 7-11 am

Collaborators and Investigators

• Sponsor: Denver Nephrologists, P.C.
• Collaborators: CM&D Pharma Limited
• Investigators: Principal Investigator: Geoffrey A Block, MD, Denver Nephrologists, PC

Publications and helpful links

General Publications

• Block GA, Persky MS, Shamblin BM, Baltazar MF, Singh B, Sharma A, Pergola P, Smits G, Comelli MC. Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease. Nephron Clin Pract. 2013;123(1-2):93-101. doi: 10.1159/000351850. Epub 2013 Jun 22.

Study record dates

Study Major Dates

• Study Start: March 1, 2011
• Primary Completion (Actual): July 1, 2011
• Study Completion (Actual): July 1, 2011

Study Registration Dates

• First Submitted: March 3, 2011
• First Submitted That Met QC Criteria: March 8, 2011
• First Posted (Estimate): March 10, 2011

Study Record Updates

• Last Update Posted (Estimate): July 22, 2011
• Last Update Submitted That Met QC Criteria: July 21, 2011
• Last Verified: March 1, 2011

More Information

Terms related to this study

• Keywords: Chronic kidney disease, phosphorus, salivary phosphorus
• Additional Relevant MeSH Terms: Urologic Diseases; Renal Insufficiency; Kidney Diseases; Renal Insufficiency, Chronic
• Other Study ID Numbers: CMD 003